Currently out of the existing stock ratings of Leah Rush Cann, 92 are a BUY (97.87%), 2 are a HOLD (2.13%).

Leah Rush Cann

Work Performance Price Targets & Ratings Chart

Analyst Leah Rush Cann, currently employed at BROOKLINE, carries an average stock price target met ratio of 52.75% that have a potential upside of 42.44% achieved within 344 days. Previously, Leah Rush Cann worked at OPPENHEIMER, CANACCORD.

Leah Rush Cann’s has documented 229 price targets and ratings displayed on 19 stocks. The coverage is on the Healthcare sector.

Most recent stock forecast was given on KYMR, Kymera Therapeutics at 07-Jul-2025.

Wall Street Analyst Leah Rush Cann

Analyst best performing recommendations are on SYRS (SYROS PHARMACEUTICALS).
The best stock recommendation documented was for MRNA (MODERNA) at 11/25/2020. The price target of $164 was fulfilled within 13 days with a profit of $54.82 (50.21%) receiving and performance score of 38.62.

Average potential price target upside

of $70.77 (78.72%) on XFOR (X4 PHARMACEUTICALS).
of $61.2 (49.62%) on SQZ (SQZ BIOTECHNOLOGIES CO).
of $48.34 (148.8%) on KYMR (KYMERA THERAPEUTICS).

AMGN Amgen CELG Celgene CTIC CTi Biopharma Corp MEIP MEI Pharma MRNA Moderna SQZ Sqz Biotechnologies Co CCCC C4 Therapeutics CRBU Caribou Biosciences KURA Kura Oncology SYRS Syros Pharmaceuticals MRTX Mirati Ther NTLA Intellia Therapeutics VSTM Verastem XFOR X4 Pharmaceuticals CNST Constellation Pharmaceuticals EPZM Epizyme EXEL Exelixis KYMR Kymera Therapeutics MRKR Marker Therapeutics

Show more stocks

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date of last PT

Price targets met ratio

Average potential upside

Average Days to Hit Target

Performance score

Terence Flynn (MORGAN STANLEY)